• Je něco špatně v tomto záznamu ?

Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects

J. Konecny, A. Misiachna, M. Chvojkova, L. Kleteckova, M. Kolcheva, M. Novak, L. Prchal, M. Ladislav, K. Hemelikova, J. Netolicky, M. Hrabinova, T. Kobrlova, JZ. Karasova, J. Pejchal, J. Fibigar, Z. Vecera, T. Kucera, P. Jendelova, P. Zahumenska,...

. 2024 ; 280 (-) : 116981. [pub] 20241018

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003033

We aimed to prepare novel dibenzo [a,d][7]annulen derivatives that act on N-methyl-d-aspartate (NMDA) receptors with potential neuroprotective effects. Our approach involved modifying the tropane moiety of MK-801, a potent open-channel blocker known for its psychomimetic side effects, by introducing a seven-membered ring with substituted base moieties specifically to alleviate these undesirable effects. Our in silico analyses showed that these derivatives should have high gastrointestinal absorption and cross the blood-brain barrier (BBB). Our pharmacokinetic studies in rats supported this conclusion and confirmed the ability of leading compounds 3l and 6f to penetrate the BBB. Electrophysiological experiments showed that all compounds exhibited different inhibitory activity towards the two major NMDA receptor subtypes, GluN1/GluN2A and GluN1/GluN2B. Of the selected compounds intentionally differing in the inhibitory efficacy, 6f showed high relative inhibition (∼90 % for GluN1/GluN2A), while 3l showed moderate inhibition (∼50 %). An in vivo toxicity study determined that compounds 3l and 6f were safe at 10 mg/kg doses with no adverse effects. Behavioral studies demonstrated that these compounds did not induce hyperlocomotion or impair prepulse inhibition of startle response in rats. Neuroprotective assays using a model of NMDA-induced hippocampal neurodegeneration showed that compound 3l at a concentration of 30 μM significantly reduced hippocampal damage in rats. These results suggest that these novel dibenzo [a,d][7]annulen derivatives are promising candidates for developing NMDA receptor-targeted therapies with minimal psychotomimetic side effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003033
003      
CZ-PrNML
005      
20250206104020.0
007      
ta
008      
250121e20241018fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2024.116981 $2 doi
035    __
$a (PubMed)39442339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Konecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
245    10
$a Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects / $c J. Konecny, A. Misiachna, M. Chvojkova, L. Kleteckova, M. Kolcheva, M. Novak, L. Prchal, M. Ladislav, K. Hemelikova, J. Netolicky, M. Hrabinova, T. Kobrlova, JZ. Karasova, J. Pejchal, J. Fibigar, Z. Vecera, T. Kucera, P. Jendelova, P. Zahumenska, E. Langore, J. Doderovic, YP. Pang, K. Vales, J. Korabecny, O. Soukup, M. Horak
520    9_
$a We aimed to prepare novel dibenzo [a,d][7]annulen derivatives that act on N-methyl-d-aspartate (NMDA) receptors with potential neuroprotective effects. Our approach involved modifying the tropane moiety of MK-801, a potent open-channel blocker known for its psychomimetic side effects, by introducing a seven-membered ring with substituted base moieties specifically to alleviate these undesirable effects. Our in silico analyses showed that these derivatives should have high gastrointestinal absorption and cross the blood-brain barrier (BBB). Our pharmacokinetic studies in rats supported this conclusion and confirmed the ability of leading compounds 3l and 6f to penetrate the BBB. Electrophysiological experiments showed that all compounds exhibited different inhibitory activity towards the two major NMDA receptor subtypes, GluN1/GluN2A and GluN1/GluN2B. Of the selected compounds intentionally differing in the inhibitory efficacy, 6f showed high relative inhibition (∼90 % for GluN1/GluN2A), while 3l showed moderate inhibition (∼50 %). An in vivo toxicity study determined that compounds 3l and 6f were safe at 10 mg/kg doses with no adverse effects. Behavioral studies demonstrated that these compounds did not induce hyperlocomotion or impair prepulse inhibition of startle response in rats. Neuroprotective assays using a model of NMDA-induced hippocampal neurodegeneration showed that compound 3l at a concentration of 30 μM significantly reduced hippocampal damage in rats. These results suggest that these novel dibenzo [a,d][7]annulen derivatives are promising candidates for developing NMDA receptor-targeted therapies with minimal psychotomimetic side effects.
650    12
$a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
650    _2
$a zvířata $7 D000818
650    12
$a neuroprotektivní látky $x farmakologie $x chemie $x chemická syntéza $7 D018696
650    12
$a dizocilpinmaleát $x farmakologie $7 D016291
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a hematoencefalická bariéra $x metabolismus $x účinky léků $7 D001812
650    _2
$a lidé $7 D006801
650    _2
$a potkani Sprague-Dawley $7 D017207
655    _2
$a časopisecké články $7 D016428
700    1_
$a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Chvojkova, Marketa $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Kleteckova, Lenka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Kolcheva, Marharyta $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Novak, Martin $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Prchal, Lukas $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Ladislav, Marek $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Hemelikova, Katarina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Netolicky, Jakub $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Hrabinova, Martina $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Kobrlova, Tereza $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
700    1_
$a Karasova, Jana Zdarova $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Fibigar, Jakub $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Vecera, Zbynek $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Jendelova, Pavla $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Zahumenska, Petra $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Langore, Emily $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Doderovic, Jovana $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic
700    1_
$a Pang, Yuan-Ping $u Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN, USA
700    1_
$a Vales, Karel $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz
700    1_
$a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 14220, Prague, Czech Republic. Electronic address: martin.horak@iem.cas.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 280 (20241018), s. 116981
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39442339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104015 $b ABA008
999    __
$a ok $b bmc $g 2263050 $s 1239040
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 280 $c - $d 116981 $e 20241018 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...